🔗 Permalink

Inventor profile of:

Peter Andersen

City:

Bronshoj

Country:

Denmark

Published Applications:

Last publication date:

2025-08-14

Top Assignees for applications by Peter Andersen

The entities that hold a legal rights for patent applications filed by inventor Andersen Peter:

STATENS SERUM INSTITUT 25 Copenhagen S, Denmark
STATENS SERUM INSTITUT 5 Copenhagen, Denmark
Statens Serum Institute 3 Copenhagen S, Denmark
Statens Serum Institut 1 , Denmark
Serum Statens Institut 1 Copenhagen S, Denmark
Statens Serum Institut 1 DK-2300 Copenhagen S, Denmark

Recent patent applications by Andersen Peter

Peter Andersen from Bronshoj, DK has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-08-14

US20250255951A1

Human necessities

Vaccines against Chlamydia sp.

#2 | 2021-07-08

US20210205433A1

Human necessities

Vaccines against Chlamydia sp.

#3 | 2019-04-04

US20190099478A1

Human necessities

Vaccines against sp

#4 | 2015-10-15

US20150290311A1

Human necessities

vaccines

#5 | 2015-04-02

US20150093407A1

Human necessities

Tuberculosis TB vaccine to prevent reactivation

#6 | 2014-09-18

US20140275478A1

Human necessities

Vaccines against Chlamydia sp.

#7 | 2014-07-24

US20140205656A1

Human necessities

MODIFIED CATIONIC LIPOSOME ADJUVANTS

#8 | 2013-06-13

US20130149324A1

Chemistry; metallurgy

THERAPEUTIC TB VACCINE

#9 | 2013-04-18

US20130095132A1

Chemistry; metallurgy

Tuberculosis vaccines comprising antigens expressed during the latent infection phase

#10 | 2012-06-21

US20120156282A1

Human necessities

EXPANDING THE T CELL REPERTOIRE TO INCLUDE SUBDOMINANT EPITOPES BY VACCINATION WITH ANTIGENS DELIVERED AS PROTEIN FRAGMENTS OR PEPTIDE COCKTAILS

#11 | 2012-05-10

US20120114687A1

Chemistry; metallurgy

Tuberculosis vaccines comprising antigens expressed during the latent infection phase

#12 | 2012-02-16

US20120039925A1

Chemistry; metallurgy

Tuberculosis TB vaccine to prevent reactivation

#13 | 2012-01-19

US20120014980A1

Human necessities

Vaccines comprising TB10.4

#14 | 2011-11-24

US20110287087A1

Human necessities

MODIFIED CATIONIC LIPOSOME ADJUVANS

#15 | 2011-10-13

US20110250224A1

Human necessities

Adjuvant combinations of liposomes and mycobacterial lipids for immunization compositions and vaccines

#16 | 2011-08-25

US20110206713A1

Chemistry; metallurgy

Tuberculosis vaccines comprising antigens expressed during the latent infection phase

#17 | 2011-01-27

US20110020384A1

Chemistry; metallurgy

Therapeutic TB vaccine

#18 | 2011-01-11

US10723908

Tuberculosis vaccine and diagnostics based on the sat-6 gene family

#19 | 2010-12-09

US20100310585A1

Human necessities

Use of monomycolyl glycerol (MMG) as an adjuvant

#20 | 2010-01-21

US20100015171A1

Human necessities

VACCINES COMPRISING TB 10.4

#21 | 2009-12-10

US20090304722A1

Chemistry; metallurgy

antigens for vaccine and diagnostic use

#22 | 2009-07-23

US20090186048A1

Chemistry; metallurgy

Tuberculosis vaccines comprising antigens expressed during the latent infection phase

#23 | 2008-10-30

US20080267990A1

Chemistry; metallurgy

TB diagnostic based on antigens from

#24 | 2008-01-10

US20080008724A1

Human necessities

Expanding the T cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails

#25 | 2007-08-09

US20070184073A1

Chemistry; metallurgy

TB diagnostic based on antigens from M. tuberculosis

#26 | 2006-06-01

US20060115847A1

Physics

Specific epitope based immunological diagnosis of tuberculosis

#27 | 2006-05-02

US9805427

Hybrids of M. tuberculosis antigens

#28 | 2006-01-31

US9804980

M. tuberculosis antigens

#29 | 2006-01-03

US10138473

TB diagnostic based on antigens from M. tuberculosis

#30 | 2005-09-01

US20050191308A1

Human necessities

Adjuvant combinations for immunization composition and vaccines

InventorID:

196789 ⎘